neuroClues

High-Level Overview

neuroClues is a French-Belgian MedTech startup developing a portable, CE-marked Class IIa medical device based on eye-tracking technology to empower clinicians with biomarkers for early detection of neurological disorders like Parkinson’s Disease, Alzheimer’s Disease, and Multiple Sclerosis—years before visible symptoms appear.[1][2][3] The device, often called a "brain stethoscope," provides non-invasive, quick analysis of eye movements in an easy-to-use clinical environment, targeting neurologists and aiming to support 10 million patients by 2030 amid rising prevalence (e.g., Parkinson’s cases doubling to 13 million).[1][3][5] It serves healthcare practitioners in Europe (currently available post-CE marking) and is pursuing US regulatory approvals, with strong growth via €4.7M seed (2021), €2.5M EIC grant plus up to €9M equity (2022), and €5M pre-Series A (2024) to enable commercial rollout.[1][2]

Origin Story

Founded in 2020 as P3Lab (rebranded to neuroClues), the company emerged from over 35 years of combined research by a team of researchers, doctors, and engineers focused on eye movement studies through modeling and experimental projects.[1][2] Frustrated by limitations in existing eye-tracking tools for clinical use, founders—including key figures who pursued eye movement research—teamed up with Antoine Pouppez to create NeuroClues™, a medical device unlocking eye-tracking's potential for early neurological diagnosis.[1] Pivotal early traction included incubation at iPEPS-ICM (Paris-Salpêtrière hospital incubator and STATION F healthtech partner), partnership with Paris Brain Institute, and international collaborations; funding momentum accelerated with the €4.7M seed in November 2021, followed by EIC support and 2024 pre-Series A.[1][2]

Core Differentiators

• Product Innovation: Portable eye-tracking device designed for clinical settings, delivering robust, instantaneous biomarkers from eye movements (e.g., anti-saccades, voluntary/reflexive saccades) backed by 60+ years and 80,000+ scientific articles linking them to neurological diseases.[1][3][6]
• Ease of Use and Accessibility: User-friendly "portable lab" with norms for interpretation, non-invasive setup for quick clinical exams, enhancing diagnosis certainty and patient follow-up—praised by scientific advisory board for bridging research to practice.[1][3][6]
• Regulatory and Scientific Edge: CE-marked Class IIa for Europe (approved for clinical use), with algorithms combining eye-tracking for "brain stethoscope" functionality; partnerships like Paris Brain Institute add credibility.[2][3][5]
• Clinical Focus: Tailored for neurologists to quantify exams objectively, addressing pain points in traditional eye-tracking for diseases like Parkinson’s, Alzheimer’s, and MS.[1][3]

Role in the Broader Tech Landscape

neuroClues rides the wave of AI-driven digital health and precision neurology, leveraging eye-tracking—a mature field with decades of evidence—to enable pre-symptomatic detection amid surging neurological disorder prevalence (1 in 3 affected globally).[1][3] Timing aligns with aging populations and post-pandemic medtech acceleration, where non-invasive biomarkers fill gaps in subjective diagnostics; market forces like EIC funding and US expansion favor scalable deep tech like this.[1][2] It influences the ecosystem by democratizing advanced research (e.g., via portable tools) for routine care, fostering collaborations across Europe/US hospitals and incubators like STATION F, and paving the way for broader adoption of eye-based biomarkers in neurology.[2][5]

Quick Take & Future Outlook

With €5M pre-Series A fueling US regulatory approvals and commercial deployment, neuroClues is poised for 2025-2030 scale toward its 10M-patient goal, potentially debuting at CES 2025 to boost visibility.[1][5] Trends like AI-biomarker integration and global medtech harmonization (e.g., FDA pathways) will propel growth, evolving its role from European pioneer to global standard-setter in early neurologic care—transforming "biomarkers in a blink" from research passion to clinical reality.[1][3]